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 22 
Highlights 23 
• This study investigated whether polyethylene-glycol (PEG) coated liposomes accumulate in 24 
the lamellar tissue during laminitis development 25 
• 99mTc-PEG-liposomes were administered to normal horses and horses with oligofructose-26 
induced laminitis 27 
• Scintigraphic examination and lamellar tissue collection demonstrated liposome 28 
accumulation in the lamellar tissue of horses with oligofructose-induced laminitis. 29 
• Liposomes may have potential for targeted lamellar drug delivery in acute laminitis 30 
Abstract 31 
Liposomes are phospholipid nanoparticles used for targeted drug delivery. This study 32 
aimed to determine whether intravenous liposomes accumulate in lamellar tissue during 33 
laminitis development in horses so as to assess their potential for targeted lamellar drug 34 
delivery. Polyethylene-glycol (PEG) coated liposomes were prepared according to the film 35 
hydration method and labelled using 
99m
Tc-hexamethyl-propylene-amine-oxime. Six horses 36 
received 10 g/kg oligofructose via nasogastric tube to induce laminitis, and four control 37 
horses received water via nasogastric tube. All horses received 300 µmol 
99m
Tc-PEG-38 
liposomes (5.5 GBq) plus 5.5 µmol/kg PEG-liposomes by slow intravenous infusion. 39 
Scintigraphic imaging was performed at 0, 6 and 12 h post-infusion. Technetium-99m 40 
liposome uptake was measured in regions of interest over the hoof, fetlock and metacarpus. 41 
At the study end-point horses were euthanased, tissue samples collected and tissue liposome 42 
levels were calculated as the percentage of the injected dose of 
99m
Tc-liposomes per kilogram 43 
of tissue. Data were analysed non-parametrically. 44 
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   All horses receiving oligofructose developed clinical and histological signs of 45 
laminitis. Technetium-99m liposome uptake in the hoof increased with time in laminitis 46 
horses (P=0.04), but decreased with time in control horses (P=0.01). Technetium-99m 47 
liposome levels in lamellar tissue from laminitis horses was 3.2-fold higher than controls 48 
(P=0.02) and were also higher in laminitis vs. control skin, muscle, jejunum, colon, and 49 
kidney (P<0.05). Liposomes accumulated in lamellar tissue during oligofructose-induced 50 
laminitis development and demonstrated potential for targeted lamellar drug delivery in acute 51 
laminitis. This study provides further evidence that lamellar inflammation occurs during 52 
laminitis development. Liposome accumulation also occurred in the skin, muscle, jejunum, 53 
colon and kidneys, suggesting systemic inflammation in this model. 54 
 55 
Keywords: Nanoparticle, Horse, Liposome, Scintigraphy, Nanotechnology 56 
  57 
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Introduction 58 
Acute laminitis is a crippling disease of the horse foot with irreversible pathology so 59 
prophylaxis is paramount. There are three broad aetiological categories of laminitis, namely, 60 
endocrinopathic, sepsis-related and supporting limb laminitis. Similar to sepsis-related organ 61 
failure in humans, sepsis-related laminitis often results in the demise of the patient after 62 
successful treatment of the primary condition. Sepsis is defined as documented or suspected 63 
infection, plus systemic manifestations of infection (Cawcutt and Peters, 2014).  64 
 65 
The oligofructose model of laminitis involves administration of 10 g/kg oligofructose 66 
by nasogastric tube, resulting in clinical signs of enterocolitis, presumptive disruption of the 67 
gastrointestinal barrier, documented endotoxaemia and subsequent laminitis development 68 
(van Eps et al., 2006; Bailey et al., 2009).  A systemic inflammatory response occurs 69 
mirroring that which occurs during human sepsis, including the classical symptoms of 70 
pyrexia, tachycardia, tachypnoea, haemoconcentration and leucocytosis (van Eps et al., 2006; 71 
Belknap, 2007; Bailey et al., 2009; Cawcutt and Peters, 2014). During the development of 72 
oligofructose-induced laminitis, endothelial activation, leukocyte infiltration and an increase 73 
in pro-inflammatory cytokine and cyclooxygenase (COX)-2 expression occur in the lamellae 74 
in common with findings seen in organ failure associated with human sepsis (Black et al., 75 
2006; Belknap et al., 2007; Tadros et al., 2012). Therefore the oligofructose model is 76 
considered to be an appropriate model for naturally-occurring sepsis-related laminitis, such 77 
that occurs secondary to diseases such as colitis (Belknap et al., 2007; Belknap and Black, 78 
2012; van Eps, 2012; Kullmann et al., 2014). 79 
 80 
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Distal limb cryotherapy prevents sepsis-related laminitis (Van Eps and Pollitt, 2004; 81 
van Eps et al., 2014; Kullmann et al., 2014), but it is labour-intensive and practically 82 
challenging. Potential therapeutic targets involved in the pathophysiology of sepsis-related 83 
laminitis have been identified and include inflammation (Belknap et al., 2007; Leise et al., 84 
2011, 2012; Visser and Pollitt, 2011; Tadros et al., 2012), proteolytic enzyme activation 85 
(Pollitt et al., 1998; Visser and Pollitt, 2012; Wang et al., 2012) and wingless-related 86 
integration site (Wnt)-pathway dysregulation (Wang et al., 2013). Pharmaceuticals directed to 87 
address these targets are available and include non-steroidal anti-inflammatory drugs, 88 
corticosteroids, signal transducer and activator of transcription (STAT) 3 inhibitors (Leise et 89 
al., 2012), protease inhibitors (Pollitt et al., 1998; De Savi et al., 2011) and Wnt-pathway 90 
agonists (Wang et al., 2013). Evaluation of these substances for laminitis prophylaxis has 91 
been hindered by their unsuitability for systemic delivery due to cost, rapid clearance, low 92 
bioavailability, inability to achieve therapeutic tissue concentrations, unwanted systemic side 93 
effects and/or degradation in the circulation (Levin et al., 2006; Nourian et al., 2010).  94 
 95 
Recent work has investigated methods of regional lamellar delivery (Nourian et al., 96 
2010; Underwood et al., 2015; C. Underwood et al, unpublished data). Despite initial 97 
promising results (Nourian et al., 2010), intraosseous infusion of the distal phalanx does not 98 
consistently yield therapeutic lamellar drug concentrations (C. Underwood et al., unpublished 99 
data). Regional limb perfusion requires frequent dosing (of each limb separately) to maintain 100 
therapeutic concentrations (Underwood et al., 2015), so the technique is not suitable for 101 
widespread clinical application. A means of lamellar drug delivery that provides sustained, 102 
therapeutic lamellar drug concentrations and has potential for clinical application is required. 103 
 104 
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Nanoparticles are ordered structures used for targeted drug delivery.  They improve 105 
the therapeutic index and safety profile of the substances they carry (Cordeiro et al., 2000; 106 
Metselaar et al., 2003; Hofheinz et al., 2005; Rose et al., 2005). Nanoparticles also provide a 107 
means of sustained delivery over a period of days or even weeks (Sahoo and Labhasetwar, 108 
2003; Bakker-Woudenberg et al., 2005; Fahmy et al., 2005). As a consequence, nanoparticle 109 
formulations may require a reduced dose compared to free drug, thus reducing the cost of 110 
expensive pharmaceuticals (Underwood and van Eps, 2012).  111 
 112 
Liposomes are phospholipid nanoparticles that form highly flexible delivery systems 113 
with the ability to carry both hydrophilic and hydrophobic pharmaceuticals. Their safety and 114 
biodistribution has been established in normal horses (Underwood et al., 2012). Small 115 
polyethylene-glycol (PEG) coated liposomes are most suitable for targeted drug delivery after 116 
intravenous (IV) administration. Following injection, a relatively small number of PEG-117 
liposomes are endocytosed by macrophages. Those evading endocytosis remain in circulation 118 
for prolonged periods of time (Arulsudar et al., 2004). Together with their small size, these 119 
long-circulating characteristics confer the ability to extravasate at sites of increased vascular 120 
permeability and facilitate accumulation in the tissue around those sites (Laverman et al., 121 
2001). This has been termed the enhanced permeability and retention (EPR) effect and is the 122 
underlying principle behind many passively targeted nanoparticle drug delivery systems.   123 
 124 
Increased vascular permeability occurs at sites of inflammation that occurs during 125 
laminitis development (Belknap et al., 2007; Visser, 2009; Faleiros et al., 2011; Tadros et al., 126 
2012). Therefore, liposomes may accumulate in lamellar tissue during laminitis development 127 
and provide a means of targeted lamellar drug delivery. The objectives of this study were (1) 128 
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to establish whether liposomes accumulate in the lamellar tissue during laminitis 129 
development in the oligofructose (OF) model of laminitis (a sepsis model), and (2) to 130 
establish the biodistribution of liposomes during sepsis in the OF model.  131 
 132 
Materials and methods 133 
The project was approved by the University of Queensland Animal Ethics Committee 134 
(approval number: SVS/117/11) that monitors compliance with the Animal Welfare Act 135 
(2001) and The Code of Practice for the care and use of animals for scientific purposes 136 
(current edition).   137 
 138 
Animals and laminitis induction 139 
Ten mature Standardbred geldings (aged 4-11 years, 395-583 kg bodyweight), with 140 
no lameness and no gross nor radiographic abnormalities of the feet were enrolled in the 141 
study. The horses were housed and fed in stables for 4 weeks prior to the experiment as 142 
previously described (van Eps and Pollitt, 2006).  143 
 144 
During the experiment the horses were housed in climate-controlled, lead lined stalls 145 
and had ad libitum access to hay and water. Six horses (laminitis group) received alimentary 146 
overload with OF (bolus dose of 10 g/kg OF via nasogastric tube, up to a maximum dose of 147 
4.2 kg) to induce laminitis as previously described (van Eps and Pollitt, 2006). Four control 148 
horses (control group) received equivalent volumes of plain water by nasogastric tube. The 149 
horses were monitored every 2 h throughout the study and heart rates, respiratory rates and 150 
temperatures were recorded every 6 h. Upon onset of Obel grade 2 lameness, defined as 151 
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lameness detectable at the walk (Obel, 1948), a single dose of phenylbutazone 152 
(Phenylarthrite, Ausrichter) was administered IV at 8 mg/kg.   153 
 154 
 Liposome preparation 155 
Dipalmitoyl phosphatidylcholine (DPPC) and PEG-(2000)-distearoyl 156 
phosphatidylethanolamine (PEG-(2000)-DSPE) were obtained from Lipoid, cholesterol and 157 
glutathione (GS-H) were obtained from Sigma. All chemicals were of reagent grade. A 158 
chloroform/methanol mixture (10:1 volumetric ratio) containing DPPC, PEG-(2000)-DSPE 159 
and cholesterol was prepared at a molar ratio of 1.85:0.15:1. A lipid film was formed by 160 
rotary evaporation followed by nitrogen flushing to remove residual organic solvent. The 161 
lipid film was dispersed at 50 °C in 100 mmol/L GS-H in 4-(2-hydroxyethyl)piperazine-1-162 
ethanesulfonic acid (HEPES) buffer (10 mmol/L HEPES, 135 mmol/L NaCl, pH 7.5) at a 163 
total lipid concentration of 100 mmol/L. Empty liposomes were dispersed in HEPES buffer 164 
only.  165 
 166 
The liposomes were sequentially sized by extrusion using a high pressure extruder 167 
(Lipex) with polycarbonate filters of 200, 100, 80 and 50 nm pore size (Whatman 168 
International). Unentrapped GS-H was removed by dialysis against HEPES buffer using 169 
Slide-A-Lyzer dialysis cassettes with a molecular cut-off of 10 kDa (Pierce). Finally, the 170 
liposomes were passed through a 0.2 mm sterile disc filter. The mean particle size was 171 
determined by dynamic light-scattering with an ALV CGS-3 system (Malvern instruments). 172 
The liposomes had a mean size of 85 nm with a polydispersity index of 0.139. Phospholipid 173 
content was determined with a phosphate assay (Fiske, 1925; Rouser et al., 1970). The final 174 
liposome preparations contained an average of 33.3 mg total lipid/mL. 175 
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 176 
Radiolabelling of liposomes 177 
Preformed G-SH-PEG-liposomes were labelled by transporting 
99m
Tc as a lipophilic 178 
99m
Tc-hexamethylpropylene-amine-oxime (HMPAO) complex through the lipid bilayer as 179 
described previously (Underwood et al., 2012). The 
99m
Tc-HMPAO was irreversibly trapped 180 
in the internal aqueous phase due to reduction by the encapsulated G-SH (Oyen et al., 1996). 181 
For each dose, 8.5 GBq of 
99m
Tc was incubated with 1 mg HMPAO (Ceretec, GE 182 
Healthcare). A dose calibrator (Atom Lab 400, Biodex) was used to measure the activity of 183 
liposomal and non-bound 
99m
Tc-HMPAO to enable calculation of labelling efficiency. 184 
  185 
 Liposome administration and monitoring procedures.  186 
All horses received 300 µmol (phospholipid) 
99m
Tc-PEG-liposomes and 5.5 µmol 187 
phospholipid/kg bodyweight unlabelled PEG-liposomes in 1 L 0.9% NaCl via IV catheter 188 
into the left jugular vein. Unlabelled liposomes were administered to increase the total 189 
phospholipid dose to a level above that at which rapid clearance is seen (Laverman et al., 190 
2000). In the laminitis group two horses received liposomes immediately after OF 191 
administration (LAM-0), two received liposomes 12 h after OF administration (LAM-12) and 192 
two received liposomes 18 h after liposome administration (LAM-18).  The liposomes were 193 
infused slowly to avoid complement mediated hypersensitivity reactions (Szebeni, 2005). 194 
Heart rate, respiratory rate and rectal temperature were monitored every 10 min for 60 min 195 
from the start of the infusion. 196 
 197 
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Imaging studies 198 
Scintigraphic examinations were performed in all horses at 1, 6 and 12 h after the start 199 
of the liposome infusion (p.i.) using a large field-of-view scintillation camera with a high 200 
resolution collimator (Technicare Omega 500 gamma camera, GE Healthcare) in a climate 201 
controlled lead-lined room. Scans were also performed at 18 and 24 h p.i. in the LAM-0 202 
group. Post-acquisition nuclear medicine software was used for image display and analysis 203 
(NuQuest v3.0 imaging software, MedX).  204 
 205 
Three-minute static images of the dorsal and lateral aspects of both forefeet were 206 
acquired at each time point with the hooves positioned a set distance from the camera. Images 207 
were stored in a 256  256 matrix and were analysed retrospectively by a blinded observer 208 
(CU) with all measurements performed in triplicate.  209 
 210 
The count density was established in regions of interest (ROI) over the hoof, fetlock, 211 
and metacarpus in each image. The count density per second (CD/s) was calculated, and 212 
corrected for both the decay and the total initial dose in each horse. The ratio of the count 213 
densities in the hoof and metacarpus (hoof:metacarpus) and the fetlock and metacarpus 214 
(fetlock:metacarpus) in each horse were calculated. Hoof wall surface temperature (HWST) 215 
was recorded before each examination using a hand-held infra-red scanner (Exergen). 216 
 217 
Liposome biodistribution  218 
Blood samples were collected directly from the right jugular vein immediately 219 
following liposome infusion and at 6 and 12 h p.i. Blood radioactivity was measured on a 220 
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shielded well scintillation gamma counter (Ludlum Instruments) and corrected for volume 221 
and decay. The half-life of 
99m
Tc-liposomes was roughly estimated by non-compartmental 222 
analysis using a log-linear model on PKSolver (China Pharmaceutical University). 223 
 224 
At the end of the study (immediately following the 12 h scintigraphic examination in 225 
the LAM-12 and LAM-18 groups and the 24 h scintigraphic examination in the LAM-0 226 
group) the horses were examined for lameness at the walk. Lameness was scored according 227 
to the Obel grading system (Obel, 1948). The horses were euthanased with pentobarbital 228 
sodium (20 mg/kg IV).  Samples of lung, liver, spleen, kidney, jejunum, colon, forelimb 229 
lamellar tissue, muscle, skin and adipose tissue were dissected immediately following 230 
euthanasia. Samples were weighed and the activity of the sample (equivalent to the amount of 231 
99m
Tc-liposomes present in the sample (Phillips et al., 1992) was measured using a shielded 232 
well scintillation gamma counter (Ludlum instruments). To correct for physical decay, an 233 
aliquot of the original injected dose was counted simultaneously. The results were expressed 234 
as percentage injected dose/kg of tissue (% ID/kg).  235 
 236 
Histological evaluation 237 
Dorsal lamellar sections from the forelimbs were fixed using 10% neutral buffered 238 
formalin, processed by routine paraffin embedding, sectioned at 4 µm and stained with 239 
haematoxylin and eosin and periodic acid–Schiff for light microscopy as previously 240 
described (Pollitt, 1996). Histological analysis was performed by a blinded observer (AVE). 241 
The severity of laminitis pathology was scored for each section using a system based on the 242 
0-3 scale previously described by Pollitt (Pollitt, 1996). 243 
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 244 
Data analyses 245 
Data were analysed using a statistical software package (GraphPad Prism 6). The data 246 
were tested for normality using D’Agostino-Pearson omnibus normality tests. Data 247 
distributions were either non-Gaussian, or group numbers were too small to presume a 248 
normal distribution, hence non-parametric tests were used. Non-paired data were compared 249 
by Mann U Whitney tests. Comparisons of repeated measured were analysed using Friedman 250 
analyses with Dunn’s post-tests. For the analysis of scintigraphic data only data from the final 251 
12 h of the LAM-0 group were used. Significance was set at P≤0.05. Unless otherwise stated, 252 
data are expressed as median [interquartile range]. 253 
 254 
Results 255 
All horses that received OF (the laminitis group) developed fever, diarrhoea and 256 
lameness (Obel grade 2-3). Median histological scores were significantly greater in the 257 
laminitis group (1.5[1-2]) compared to the control group (0[0-0.38], P=0.01).  258 
 259 
Radiolabelling efficiency was 82[63-90]% and the median activity of the 
99m
Tc-260 
liposomes immediately prior to infusion was 5.5[4.5-6.6] GBq. There was no difference in 261 
the median radioactivity of the 
99m
Tc-liposomes administered to laminitis versus control 262 
horses (5.0[4.2-6.8] GBq vs. 6.1[4.8-6.4] GBq, respectively). Each horse received the full 263 
liposome dose and the median infusion time was 38[35-49] min. No adverse reactions were 264 
detected and there were no significant changes in heart rate, respiratory rate or temperature 265 
during the infusion (data not shown).  266 
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 267 
Based on the radioactivity in sequential blood samples (corrected for decay), the 268 
99m
Tc-liposomes exhibited slow elimination from the circulation with a median half-life of 269 
22.9[8.4-32.4] h. Due to the limited number of time-points, these half-lives are only a rough 270 
estimate. There was no difference in the median half-life between the laminitis and control 271 
groups. There was a decrease in the blood radioactivity (corrected for decay) with time in the 272 
laminitis group (P<0.001; Fig. 1). At 12 h p.i. the blood radioactivities in laminitis horses 273 
were lower than those in control horses (P=0.01; Fig. 1).    274 
 275 
The scintigraphic images demonstrated subjective diffuse increased 
99m
Tc-liposome 276 
uptake in the hoof and distal limb of laminitis horses compared to controls; evident at 6 h, 277 
and more marked at 12 h p.i. (Fig. 2).  In the laminitis group the CD/s increased with time in 278 
the dorsal hoof and fetlock ROIs (P<0.01; Figs. 3A and B). Conversely in control horses the 279 
CD/s in the dorsal hoof, fetlock and metacarpal ROIs decreased with time, and the CD/s in 280 
the lateral hoof ROI also decreased with time p.i (P<0.05; Figs. 3 A-C). The CD/s in the 281 
lateral hoof ROIs were higher in laminitis horses compared to controls at 6 and 12 hours p.i. 282 
(P=0.02; Fig. 3D). The lateral hoof:metacarpal and fetlock:metacarpal CD/s ratios were 283 
higher in laminitis horses compared to controls at 12 h (1.9[1.8-2.0] vs. 1.5[1.4-1.6] and 284 
1.5[1.4-1.8] vs. 1.1[1.0-1.1], respectively, P=0.03). There was no change in HWST with 285 
time, and there was no difference in HWST between laminitis and control horses at any time-286 
point. 287 
 288 
Page 13 of 26
14 
 
 The 
99m
Tc-liposomal levels in lamellar tissue of laminitis horses were higher than 289 
those in controls (0.21[0.14-0.3] %ID/kg vs. 0.065[0.06-0.11] %ID/kg, respectively; 290 
P=0.019; Fig. 4). Lamellar 
99m
Tc-liposome levels were highest when the liposomes were 291 
administered at 18 h p.i; with a 4.8 fold increase compared to control horses (Fig. 5), however 292 
the numbers were too small for statistical analyses. There were increased 
99m
Tc-liposome 293 
levels in the skin, muscle, jejunum, colon and kidney of laminitis horses compared to controls 294 
(P<0.05; Fig. 4). There was a trend towards increased 
99m
Tc-liposome levels in the liver of 295 
laminitis horses compared to controls, and towards decreased 
99m
Tc-liposome levels in the 296 
blood of laminitis horses compared to controls (P=0.06; Fig. 4).  297 
 298 
Discussion 299 
This study demonstrates that liposomes accumulate in the lamellar tissue during the 300 
development of sepsis-related laminitis using the OF experimental model. This conclusion is 301 
supported by both the scintigraphic imaging studies and the tissue biodistribution data. 302 
Previous studies have reported evidence of lamellar inflammation during laminitis 303 
development (Black et al., 2006; Belknap et al., 2007; Leise et al., 2011; Visser and Pollitt, 304 
2011; Tadros et al., 2012).  The accumulation of liposomes in lamellar tissue provides further 305 
evidence that lamellar inflammation and increased vascular permeability occurs during 306 
laminitis development in the OF model. 307 
 308 
The primary objective of this study was to evaluate whether liposomes accumulate in 309 
(and have potential for) targeted lamellar drug delivery. The increased lamellar liposome 310 
levels in laminitis horses at 12 h p.i indicates that liposomal drug delivery systems have 311 
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potential to yield sustained lamellar drug concentrations. Recent studies performed in our 312 
laboratory investigated lamellar marimastat concentrations after IV administration of 0.23 313 
mg/kg bodyweight (104 mg/450 kg horse) (Underwood et al., 2015). If the same dose was 314 
administered in liposomes at 18 h post-OF, based on the lamellar liposome levels in the 315 
LAM18 group (0.31% ID/kg), the lamellar marimastat concentration would be 332 ng/g 316 
tissue at 12 h post injection.  317 
 318 
Although these calculations are merely speculative, this exceeds both the 319 
concentrations achieved 12 h after RLP and the concentration necessary for inhibition of 90% 320 
of lamellar MMP-2 and MMP-9 (Underwood et al., 2015; C. Underwood et al., unpublished 321 
data). Additionally, as reported in previous studies investigating liposome accumulation in 322 
inflammation, liposomes would probably continue to accumulate in the following 12h 323 
resulting in further increases in lamellar drug concentrations (Oyen et al., 1996; Boerman et 324 
al., 1997; Erdogan et al., 2000).  325 
 326 
There were no adverse reactions to liposome administration, and no changes in heart 327 
rate, respiratory rate or temperature; adding to the evidence from previous studies 328 
(Underwood et al., 2012; Burton, 2013) that slow IV liposome administration is safe in 329 
horses. Therefore, based on this preliminary study liposomes appear to have potential for 330 
lamellar drug delivery.  331 
 332 
The subjective increase in lamellar liposome levels between LAM-0, LAM-12 and 333 
LAM-18 groups, respectively, suggests there is a temporal increase in lamellar inflammation 334 
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post-OF administration, consistent with previous reports (Visser, 2009). Liposomes were 335 
administered immediately following, then at 12 h and 18 h after OF administration to achieve 336 
high circulating liposome levels coinciding with the onset of lamellar inflammation (Visser, 337 
2009).  The highest uptake was achieved when liposomes were administered at 18 h post-OF.  338 
By 18 h the horses were exhibiting Obel grade 1-2 lameness, which may be too late for 339 
delivery of laminitis prophylactics. However, prophylactic digital cryotherapy is effective 340 
when initiated at Obel grade 2 lameness (18.5 h post-OF administration; van Eps et al., 341 
2014), so it is possible that a pharmaceutical means of laminitis prophylaxis would still be 342 
effective at this stage. Further work is needed to evaluate the optimal time-point for 343 
administration of liposomal-formulations of drugs for laminitis prophylaxis. 344 
 345 
The 3.2 fold increase in the liposome levels in the lamellar tissue of laminitis horses 346 
compared to controls is somewhat lower than that the 24-fold increase reported in infected 347 
muscle in an equine focal infection model (Underwood, 2011). This initially seems somewhat 348 
discouraging; however, there are three key points to consider: firstly, liposome accumulation 349 
depends on the intensity of the inflammatory response (Oyen et al., 1996); focal infection 350 
models involve established inflammation, whereas in the present study liposomes were 351 
administered before or during the early stages of inflammation. Secondly, the biodistribution 352 
data in the focal infection study was obtained at 24 h p.i. whereas most of the data in this 353 
study were collected at 12 h p.i. (LAM-12 and LAM-18). Liposomes accumulate gradually 354 
with time (Boerman et al., 1997; Oyen et al., 1996). In a mouse focal infection model the 355 
abscess:control muscle ratio increased from 2.2 at 6 h p.i., to 11.7 at 24 h p.i. (Erdogan et al., 356 
2000); therefore, it is probable if sampled at a later time-point there would be greater lamellar 357 
accumulation of liposomes. Thirdly, as lamellar inflammation and laminitis pathology are 358 
focused at the dermoepidermal interface (Pollitt, 1996; Faleiros et al., 2011), greater liposome 359 
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accumulation may be present at this target site than in the lamellar tissue as a whole 360 
(Metselaar et al., 2003). 361 
 362 
Acute laminitis shares many characteristics with sepsis-related organ failure and 363 
systemic inflammatory response syndrome (SIRS) in humans (Belknap and Black, 2012; 364 
Tadros et al., 2012; Cawcutt and Peters, 2014). The accumulation in skin, muscle, jejunum 365 
colon and kidney, plus the trend towards increased hepatic liposome levels is supportive of a 366 
systemic inflammatory response resulting in inflammation and increased vascular 367 
permeability in these organs. To the authors’ knowledge this is the first study to investigate 368 
liposomal biodistribution in an animal sepsis model.  369 
 370 
The accumulation of liposomes in multiple organs in our study indicates that 371 
liposomes may have potential for targeted drug delivery to prevent sepsis related organ 372 
failure in other species. It is, however, interesting that there was a more profound increase in 373 
liposome accumulation (compared with controls) in the lamellar tissue compared with all the 374 
other studied tissues.  This indicates that the inflammatory response and increase in vascular 375 
permeability in lamellar tissue are unique.   376 
 377 
Increased interleukin (IL)-1β, IL-6 IL-8, IL-10 and tumour necrosis factor (TNF)-α 378 
gene expression has been reported previously in liver and lung of horses with OF-induced 379 
laminitis (Tadros et al., 2012). Interestingly, in the present study, there was no evidence of 380 
liposome accumulation in the lung. Normal horses demonstrate high pulmonary liposome 381 
uptake (Underwood et al., 2012), most probably due to endocytosis of liposomes by the 382 
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increased numbers of pulmonary intravascular macrophages (PIMs) present in the horse 383 
(Longworth et al., 1994). During sepsis, PIMs are activated and endocytose 384 
lipopolysaccharide and bacteria (Tsokos, 2003; Parbhakar et al., 2005).  Therefore, it is 385 
probable that during the development of OF-induced laminitis PIMs have already been 386 
activated and are unavailable to endocytose liposomes. This reduction in liposomal 387 
endocytosis may counter-balance the liposomes extravasating into the pulmonary 388 
parenchyma due to inflammation-associated increases in vascular permeability.  389 
 390 
Interestingly, the median lung uptake in the LAM-18 group appeared lower than that 391 
in the LAM-0 group (1.2[0.95-1.45] % ID/kg vs. 1.87 [1.59-2.15] % ID/kg, respectively), 392 
potentially indicative of reduced liposomal endocytosis uptake at 18 h due to saturation of 393 
PIMs in the systemic inflammatory response prior to liposome administration. However, the 394 
numbers were too small for statistical analyses so further studies are necessary to evaluate 395 
this hypothesis. 396 
 397 
Limitations of our study include the small numbers of horses, particularly the low 398 
numbers in each of the LAM groups, and the limited study duration of only 12 h p.i.  Further 399 
investigations of liposomal delivery systems for sustained lamellar drug delivery are 400 
warranted. These should focus on determining free and liposome-encapsulated drug 401 
concentrations at multiple time-points over a prolonged period (>24 h). When considering the 402 
scintigraphic data, it is important to note that the radiopharmaceutical uptake in the hoof ROI 403 
includes all sources of radioactivity within the hoof, including blood in the vascular system, 404 
along with a mild shielding effect of the hoof wall. Changes in perfusion occur during 405 
laminitis development and may have affected scintigraphic data (Van Eps and Pollitt, 2004). 406 
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Although, artefactual alterations in the scintigraphic data due to changes in perfusion cannot 407 
be definitively ruled out, the lack of significant changes in HWST (an indicator of digital 408 
vascular perfusion), and the reduction in blood activity with time suggest the increase in CD/s 409 
in the hoof ROIs of laminitis horses was attributable to liposome accumulation rather than 410 
increased perfusion. The tissue biodistribution data more accurately represent liposome levels 411 
in specific tissues. However, these could still have been altered by residual blood in the tissue 412 
and changes in lamellar perfusion. Perfusion of the disarticulated limbs with saline may have 413 
further helped to remove any residual blood from the lamellar tissue. This was attempted in 414 
one forelimb of the initial two horses, however, it was not practical and did not appear to alter 415 
the % ID/kg lamellar tissue (0.09 [0.08-0.1]% in the perfused limbs vs. 0.07 [0.07-0.08] % in 416 
the non-perfused limbs). Therefore, it was considered unlikely that changes in perfusion had 417 
a significant effect on lamellar biodistribution data; further investigation would be needed to 418 
definitively rule this out. 419 
 420 
Conclusions 421 
IV liposome administration to horses with OF-induced laminitis resulted in liposome 422 
accumulation in the lamellar tissue. The degree of liposome accumulation indicates that 423 
liposomes have potential for targeted drug delivery to lamellar tissue. With further 424 
experimental validation liposomal drug delivery systems could be the first clinically 425 
applicable method for delivering sustained therapeutic concentrations of pharmaceuticals 426 
with lamellar targets, including drugs with potential for laminitis prophylaxis, analgesics and 427 
anti-inflammatories. Liposomes also accumulate in other tissues undergoing inflammation 428 
and may therefore be of value as a drug delivery system in sepsis related organ failure in 429 
other species. 430 
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Figure legends 591 
 592 
Fig. 1. Decay corrected radioactivity in sequential blood samples following 
99m
Tc-liposome 593 
infusion in laminitis (grey circles) and control (black squares) horses. At 12 h post injection 594 
(p.i.) the blood radioactivity in the laminitis group was lower than that in the control group 595 
(*; P=0.01), and lower than the activity immediately p.i. in the laminitis group (^; P=0.001). 596 
Data are expressed as medians ± interquartile range. 597 
 598 
Fig. 2. Dorsal scintigraphic images from one of the control horses (A-C) and one of the 599 
laminitis horses (D-F) in the study. Images A and D were obtained at 1 h post injection (p.i.), 600 
B and E at 6 h p.i. and C&F at 12 h p.i. Images are corrected for acquisition time, decay and 601 
initial dose.  602 
 603 
Fig. 3. Variations in the median count density/s (CD/s) (± inter-quartile range), in 604 
scintigraphic regions of interest (ROIs), in laminitis (grey circles) and control (black squares) 605 
horses over time. All data are corrected for decay and initial dose.  There was an increase in 606 
the CD/s in dorsal hoof (A) and dorsal fetlock (B) ROIs of laminitis horses over time (*; 607 
P<0.01) and a decrease in the CD/s in the dorsal hoof (A) and fetlock (B) and metacarpal (C) 608 
ROIs of control horses over time (*; P<0.01).). The CD/s in the lateral hoof ROI (D) of 609 
control horses decreased with time, (*; P<0.05) and was lower than that in laminitis horses at 610 
6 and 12 h post injection  (^; P=0.02). Data are expressed as medians ± interquartile range. 611 
 612 
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Fig. 4. The median liposome levels (expressed as percentage injected dose per kilogram [% 613 
ID/kg]) in various tissues in laminitis vs. control horses (LAM-0 [triangles], LAM-12 614 
[circles], LAM-18 [diamonds] and control groups [black squares]). The % ID/kg was higher 615 
in lamellae (A), skin (B), muscle (C), jejunum (D), colon (E) and kidney (F) of laminitis 616 
horses (P<0.05). There were trends towards an increased % ID/kg in the liver (G) and a 617 
decreased % ID/kg in the blood (H) of laminitis horses (P=0.06). 618 
 619 
Fig. 5. Lamellar liposome levels appeared to increase when liposomes were administered at 620 
later time-points post-oligofructose administration (LAM-0: horses that received liposomes at 621 
the time of oligofructose administration; LAM-12: horses that received liposomes12 h after 622 
oligofructose administration; LAM-18: horses that received liposomes 18 h after OF 623 
administration; CON: control horses that did not receive oligofructose). The bars are labelled 624 
with the lamellar liposome levels in that group compared to controls. Data are expressed as 625 
medians ± interquartile range. 626 
 627 
 628 
 629 
 630 
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